1
|
Pei Z, Zhou R, Yao W, Dong S, Liu Y, Gao Z. Different exercise training intensities prevent type 2 diabetes mellitus-induced myocardial injury in male mice. iScience 2023; 26:107080. [PMID: 37416463 PMCID: PMC10320508 DOI: 10.1016/j.isci.2023.107080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Revised: 04/29/2023] [Accepted: 06/06/2023] [Indexed: 07/08/2023] Open
Abstract
Type 2 diabetes mellitus (T2DM) usually develop myocardial injury and that exercise may have a positive effect on cardiac function. However, the effect of exercise intensity on cardiac function has not yet been fully examined. This study aimed to explore different exercise intensities on T2DM-induced myocardial injury. 18-week-old male mice were randomly divided into four groups: a control group, the T2DM, T2DM + medium-intensity continuous training (T2DM + MICT), and T2DM + high-intensity interval training (T2DM + HIIT) groups. In the experimental group, mice were given high-fat foods and streptozotocin for six weeks and then divided into two exercise training groups, in which mice were subjected to exercise five days per week for 24 consecutive weeks. Finally, metabolic characteristics, cardiac function, myocardial remodeling, myocardial fibrosis, oxidative stress, and apoptosis were analyzed. HIIT treatment improved cardiac function and improved myocardial injury. In conclusion, HIIT may be an effective means to guard against T2DM-induced myocardial injury.
Collapse
Affiliation(s)
- Zuowei Pei
- Department of Cardiology, Central Hospital of Dalian University of Technology, Dalian, China
- Department of Central Laboratory, Central Hospital of Dalian University of Technology, Dalian, China
| | - Rui Zhou
- Department of Internal Medicine, Affiliated Zhong Shan Hospital of Dalian University, Dalian, China
| | - Wei Yao
- Department of Internal Medicine, Affiliated Zhong Shan Hospital of Dalian University, Dalian, China
| | - Shuang Dong
- Department of Cardiology, Central Hospital of Dalian University of Technology, Dalian, China
| | - Yingshu Liu
- Department of Endocrinology, Central Hospital of Dalian University of Technology, Dalian, China
| | - Zhengnan Gao
- Department of Endocrinology, Central Hospital of Dalian University of Technology, Dalian, China
| |
Collapse
|
2
|
Hwang J, Oh YS, Park HS, Choi JI, Lee YS, Choi EK, Shin DG, On YK, Kim TH, Park HW, Cho MS, Bae MH, Han S. Comparing the Efficacy of Carvedilol and Flecainide on the Treatment of Idiopathic Premature Ventricular Complexes from Ventricular Outflow Tract: A Multicenter, Randomized, Open-Label Pilot Study. J Clin Med 2023; 12:jcm12082887. [PMID: 37109225 PMCID: PMC10144596 DOI: 10.3390/jcm12082887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/10/2023] [Accepted: 04/14/2023] [Indexed: 04/29/2023] Open
Abstract
The mechanism of premature ventricular complexes (PVC) occurring in the ventricular outflow tract (OT) is related to an intracellular calcium overload and delayed afterdepolarizations that lead to triggered activity. The guidelines recommend using beta-blockers and flecainide for idiopathic PVCs, but they also acknowledge the limited evidence supporting this recommendation. We conducted a multicenter, randomized, open-label pilot study comparing the effect of carvedilol and flecainide on OT PVC, which are widely used to treat this arrhythmia. Patients with a 24 h Holter recording a PVC burden ≥ 5%, which showed positive R waves in leads II, III, and aVF, and without structural heart disease were enrolled. They were randomly assigned to the carvedilol or flecainide group, and the maximum tolerated dose was administered for 12 weeks. A total of 103 participants completed the protocol: 51 with carvedilol and 52 with flecainide. After 12 weeks of treatment, the mean PVC burden significantly decreased in both groups: 20.3 ± 11.5 to 14.6 ± 10.8% with carvedilol (p < 0.0001) and 17.1 ± 9.9 to 6.6 ± 9.9% with flecainide (p < 0.0001). Both carvedilol and flecainide effectively suppressed OT PVCs in patients without structural heart disease, with flecainide showing a superior efficacy compared to carvedilol.
Collapse
Affiliation(s)
- Jongmin Hwang
- Cardiovascular Center, Keimyung University Dongsan Hospital, Daegu 42601, Republic of Korea
| | - Yong-Seog Oh
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Hyoung-Seob Park
- Cardiovascular Center, Keimyung University Dongsan Hospital, Daegu 42601, Republic of Korea
| | - Jong-Il Choi
- Arrhythmia Center, Korea University Medical Center Anam Hospital, Seoul 02841, Republic of Korea
| | - Young Soo Lee
- Department of Cardiology, Catholic University of Daegu, Daegu 42472, Republic of Korea
| | - Eue-Keun Choi
- Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea
| | - Dong-Gu Shin
- Division of Cardiology, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea
| | - Young Keun On
- Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
| | - Tae-Hoon Kim
- Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
| | - Hyung Wook Park
- Department of Cardiology, Chonnam National University Hospital, Gwangju 61469, Republic of Korea
| | - Min Soo Cho
- Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea
| | - Myung Hwan Bae
- Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea
| | - Seongwook Han
- Cardiovascular Center, Keimyung University Dongsan Hospital, Daegu 42601, Republic of Korea
| |
Collapse
|
4
|
Wang Z, Zhu Y, Zhang Y, Zhang J, Ji T, Li W, Li W. Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM. Biomed Pharmacother 2020; 127:110081. [PMID: 32244194 DOI: 10.1016/j.biopha.2020.110081] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Revised: 02/24/2020] [Accepted: 03/05/2020] [Indexed: 12/15/2022] Open
Abstract
Diabetic cardiomyopathy (DCM) is one of the main complications of type 2 diabetes mellitus (T2DM), and it is also one of the main causes of heart failure and death in advanced diabetes. The myocardial lipotoxic injury induced by abnormal lipid metabolism plays an important role in the occurrence and development of DCM, such as myocardial inflammation and fibrosis, ultimately leading to myocardial remodeling and cardiac insufficiency. Astragaloside IV (AS-IV) has many pharmacological effects such as anti-oxidation, anti-inflammatory, immune regulation, and anti-ischemic brain damage. This study was performed to investigate whether AS-IV could prevent T2DM-induced cardiomyopathy and regulate the abnormal myocardial lipid metabolism in diabetes. In this study, the T2DM model was induced by feeding with high-fat food and injected with low-dose STZ in rats. Then the model rats were treated with AS-IV and metformin (Met) for 8 weeks. The results showed that AS-IV improved cardiac systolic and diastolic function, and ameliorated the cardiac histopathological changes in the T2DM rats. Moreover, AS-IV significantly improved circulating TC, TG and HDL levels and cardiac lipid accumulation in T2DM rats as well as in high-fat diet (HFD) rats. Furthermore, AS-IV significantly inhibited the expressions of TNF-α, IL-6 and IL-1β and myocardial fibrosis in T2DM rats, which might be attributed to the improvement of myocardial lipid metabolism, ultimately improving cardiac function in T2DM rats. Taken together, these data suggested that AS-IV has protective effects on T2DM-induced myocardial injury in rats, and its mechanism may be related to the improvement of lipid metabolism in cardiomyocytes.
Collapse
Affiliation(s)
- Zhongyuan Wang
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China
| | - Yunfeng Zhu
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China
| | - Yanhua Zhang
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China
| | - Jie Zhang
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China
| | - Tianjiao Ji
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China
| | - Weizu Li
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China.
| | - Weiping Li
- Key Laboratory of Anti-Inflammatory and Immunopharmacology, Ministry of Education, Department of Pharmacology, Basic Medicine College, Anhui Medical University. Hefei, 230032, Anhui, China; Anqing Medical and Pharmaceutical College, Anqing, 246052, Anhui, China.
| |
Collapse
|
5
|
Fröhlich H, Zhao J, Täger T, Cebola R, Schellberg D, Katus HA, Grundtvig M, Hole T, Atar D, Agewall S, Frankenstein L. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. Circ Heart Fail 2015; 8:887-96. [PMID: 26175538 DOI: 10.1161/circheartfailure.114.001701] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 06/25/2015] [Indexed: 01/11/2023]
Abstract
BACKGROUND β-Blockers exert a prognostic benefit in the treatment of chronic heart failure. Their pharmacological properties vary. The only substantial comparative trial to date-the Carvedilol or Metoprolol European Trial-has compared carvedilol with short-acting metoprolol tartrate at different dose equivalents. We therefore addressed the relative efficacy of equal doses of carvedilol and metoprolol succinate on survival in multicenter hospital outpatients with chronic heart failure. METHODS AND RESULTS Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany. Patients were individually matched on both the dose equivalents and the respective propensity scores for β-blocker treatment. During a follow-up for 17 672 patient-years, it was found that 304 (27.2%) patients died in the carvedilol group and 1066 (36.8%) in the metoprolol group. In a univariable analysis of the general sample, metoprolol therapy was associated with higher mortality compared with carvedilol therapy (hazard ratio, 1.49; 95% confidence interval, 1.31-1.69; P<0.001). This difference was not seen after multivariable adjustment (hazard ratio, 0.93; 95% confidence interval, 0.57-1.50; P=0.75) and adjustment for propensity score and dose equivalents (hazard ratio, 1.06; 95% confidence interval, 0.94-1.20; P=0.36) or in the propensity and dose equivalent-matched sample (hazard ratio, 1.00; 95% confidence interval, 0.82-1.23; P=0.99). These results were essentially unchanged for all prespecified subgroups. CONCLUSIONS In outpatients with chronic heart failure, no conclusive association between all-cause mortality and treatment with carvedilol or metoprolol succinate was observed after either multivariable adjustment or multilevel propensity score matching.
Collapse
Affiliation(s)
- Hanna Fröhlich
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Jingting Zhao
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Tobias Täger
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Rita Cebola
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Dieter Schellberg
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Hugo A Katus
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Morten Grundtvig
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Torstein Hole
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Dan Atar
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Stefan Agewall
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.)
| | - Lutz Frankenstein
- From the Department of Cardiology, University of Heidelberg, Heidelberg, Germany (H.F., J.Z., T.T., R.C., D.S., L.F.); Medical Department, Innlandet Hospital Trust Division Lillehammer, Lillehammer, Norway (M.G.); Medical Faculty, Norwegian University of Science and Technology (NTNU), Trondheim, Norway (T.H.); Medical Clinic, Helse Møre and Romsdal HF, Ålesund, Norway (T.H.); and Department of Cardiology, Oslo University Hospital, Ulleval and Institute of Clinical Sciences, University of Oslo, Oslo, Norway (D.A., S.A.).
| |
Collapse
|